Issued 2026-08-13 at $14.39 · now $14.73 (2026-08-13, +2.4% since)
Based on its own history, a month from the 2026-08-13 close, CLYM has typically landed between $9.91 and $21.25 — a range of −31.1% to +47.7% from the issuance price $14.39.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
463 overlapping 1 month windows · 2024-09-09 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($14.39) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where CLYM has typically landed a month from the 2026-08-13 close of $14.39 — the range is history, not a prediction.
- now $14.73 (+2.4%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $14.46 (+0.5%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $11.87–$17.06
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $9.91–$21.25
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-11-29 | −44.3% | −44.3% | +0.9% |
| 2024-09-20 | −43.1% | −43.1% | +0.0% |
| 2024-11-27 | −42.5% | −42.5% | +1.2% |
| 3 best | |||
| 2025-11-20 | +183.2% | −5.2% | +183.2% |
| 2025-11-24 | +175.6% | −6.8% | +178.4% |
| 2025-11-25 | +173.9% | −8.9% | +173.9% |
463 overlapping windows · 2024-09-09 – 2026-08-13 · not cherry-picked
Pending catalysts
- August 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) (source, as of 2026-08-14)
- September 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) (source, as of 2026-08-14)
- October 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~2 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.